BR112013004258A2 - cristal, composição farmacêutica, e, agente anticâncer - Google Patents

cristal, composição farmacêutica, e, agente anticâncer

Info

Publication number
BR112013004258A2
BR112013004258A2 BR112013004258A BR112013004258A BR112013004258A2 BR 112013004258 A2 BR112013004258 A2 BR 112013004258A2 BR 112013004258 A BR112013004258 A BR 112013004258A BR 112013004258 A BR112013004258 A BR 112013004258A BR 112013004258 A2 BR112013004258 A2 BR 112013004258A2
Authority
BR
Brazil
Prior art keywords
crystal
pharmaceutical composition
cancer agent
hsp90
anticancer agent
Prior art date
Application number
BR112013004258A
Other languages
English (en)
Inventor
Hitoshi Ohki
Nobuyuki Suzuki
Yasusi Ueda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112013004258A2 publication Critical patent/BR112013004258A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

cristal, composição farmacêutica, e, agente anticâncer. é fornecido cristal de um composto de pirazolo-pirimidina tricíclico que inibe a ação de hsp90. a presente invenção fornece um cristal de 2-{4-amino-2-[(3-cloro-4-metóxi-5-metilpiridin-2-il)metil]-2,7-di-idro-6-tia-1,2,3,5,-tetra-azabenzo-[cd]azuleno-8-il}-n-metilacetamida que inibe a atividade de atpase de hsp90 e tem a atividade antitumoral e um medicamento, agente anticâncer e os semelhantes que contenham o mesmo.
BR112013004258A 2010-08-23 2011-08-22 cristal, composição farmacêutica, e, agente anticâncer BR112013004258A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010186459 2010-08-23
PCT/JP2011/068889 WO2012026433A1 (ja) 2010-08-23 2011-08-22 三環性ピラゾロピリミジン誘導体のフリー体結晶

Publications (1)

Publication Number Publication Date
BR112013004258A2 true BR112013004258A2 (pt) 2016-08-02

Family

ID=45723432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004258A BR112013004258A2 (pt) 2010-08-23 2011-08-22 cristal, composição farmacêutica, e, agente anticâncer

Country Status (9)

Country Link
US (2) US8846703B2 (pt)
EP (1) EP2610259A4 (pt)
JP (1) JPWO2012026433A1 (pt)
KR (1) KR20130099006A (pt)
CN (1) CN103154003A (pt)
BR (1) BR112013004258A2 (pt)
CA (1) CA2809388A1 (pt)
TW (1) TW201213334A (pt)
WO (1) WO2012026433A1 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973788A1 (en) 1997-04-02 2000-01-26 Amersham Pharmacia Biotech UK Limited Tricyclic base analogues
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
MXPA05005425A (es) 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
ES2399241T3 (es) 2004-11-18 2013-03-26 Synta Pharmaceuticals Corporation Compuestos de triazol que modulan la actividad de HSP90
RU2420530C2 (ru) * 2006-09-19 2011-06-10 Дайити Санкио Компани, Лимитед Производное пиразолопиримидина
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
EP2109612B1 (en) 2007-02-01 2010-11-10 AstraZeneca AB 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US8742133B2 (en) 2007-08-13 2014-06-03 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
JP2009256323A (ja) * 2008-03-17 2009-11-05 Daiichi Sankyo Co Ltd ピラゾロピリミジン誘導体
RU2520966C2 (ru) * 2009-02-25 2014-06-27 Дайити Санкио Компани, Лимитед Производное трициклического пиразолопиримидина

Also Published As

Publication number Publication date
JPWO2012026433A1 (ja) 2013-10-28
EP2610259A4 (en) 2014-01-08
WO2012026433A1 (ja) 2012-03-01
EP2610259A1 (en) 2013-07-03
KR20130099006A (ko) 2013-09-05
US8846703B2 (en) 2014-09-30
CA2809388A1 (en) 2012-03-01
US20140371249A1 (en) 2014-12-18
US20130211084A1 (en) 2013-08-15
CN103154003A (zh) 2013-06-12
TW201213334A (en) 2012-04-01

Similar Documents

Publication Publication Date Title
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BR112018071155A2 (pt) formas de dosagem de antagonista opioide de liberação modificada
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
IN2014MN01919A (pt)
NI201400032A (es) Piridopirazinas anticancerígenas via la
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
IN2014CN03919A (pt)
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
BR112013017302A2 (pt) formulações de imunossupressor
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
PH12015501386A1 (en) Tricyclic compounds
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MX359436B (es) Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol.
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
RS20130034A1 (en) PHARMACEUTICAL MIXTURE FOR LONG TERMETASIDINE RELEASE

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.